ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Polivy® with R-CHP significantly improves lymphoma outcomes
August 10, 2021Polivy with MabThera/Rituxan and R-CHP is the first regimen in 20 years to improve significantly outcomes in a previously untreated form of lymphoma, Phase III study shows. -
NICE does not recommend polatuzumab vedotin to treat lymphoma
March 03, 2020NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma. -
Polivy Chemoimmunotherapy Regimen Approved to Treat DLBCL
June 12, 2019Polivy Chemoimmunotherapy Regimen Approved to Treat DLBCL. -
FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma
June 11, 2019FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma.
Pharma Sources Insight January 2025
